Literature DB >> 15945082

MIB-1 and PCNA immunostaining as a diagnostic adjunct to cervical Pap smear.

M M Goel1, Anju Mehrotra, Uma Singh, H P Gupta, J S Misra.   

Abstract

The present study was done to determine the role of MIB-1 (Molecular Immunology Borstel) and proliferating cell nuclear antigen (PCNA) proliferative index as a diagnostic adjunct to cervical Papanicolaou (Pap) smear for the identification of ascending grades of cervical intraepithelial neoplasia (CIN) developing into cancer in the human uterine cervix. A total of 49 adequate Pap smears with consensus diagnosis were destained for immunocytochemical staining (MIB-1 and PC10). Staining was done by streptavidin-biotin method after antigen retrieval. MIB-1 and PC10 labeling index (LI) were calculated in each case and divided into three groups, i.e., <10%, 10-20%, and >20%, respectively. Statistical analysis was done by using the SPSS 10.0 package. The comparisons were made using analysis of variance (ANOVA) and independent sample t-test. Bivariate and Pearson's correlation coefficient were used to obtain correlations between different groups. Out of 49 cases, 40 cases (81.6%) showed positive immunostaining with MIB-1 and PCNA. Proliferative LI of MIB-1 and PCNA increased with the ascending grades of CIN lesions to carcinoma. The highest proliferative index (mean +/- SD) for PCNA and MIB-1 were observed for the carcinoma group (PCNA LI, 39.200 +/- 1.6865; MIB-1LI, 35.300 +/- 1.8886). A significant positive correlation between ascending grades of squamous intraepithelial lesion (SIL) and labeling indices of markers (r = 0.87 for MIB-1 and r = 0.88 for PCNA) suggests that MIB-1/PCNA proliferative markers can be used as an adjunct to cytomorphological interpretation of conventional cervical Pap smear. 2005 Wiley-Liss, Inc

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15945082     DOI: 10.1002/dc.20218

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  7 in total

Review 1.  Antigen retrieval immunohistochemistry: review and future prospects in research and diagnosis over two decades.

Authors:  Shan-Rong Shi; Yan Shi; Clive R Taylor
Journal:  J Histochem Cytochem       Date:  2011-01       Impact factor: 2.479

2.  Early detection of cervical carcinomas: finding an overall approach.

Authors:  Nicolas Wentzensen; Stefanie J Klug
Journal:  Dtsch Arztebl Int       Date:  2008-09-12       Impact factor: 5.594

3.  Immunohistochemical Expression of Cell Proliferating Nuclear Antigen (PCNA) and p53 Protein in Cervical Cancer.

Authors:  Goel Madhumati; Somani Kavita; Mehrotra Anju; Singh Uma; Mehrotra Raj
Journal:  J Obstet Gynaecol India       Date:  2012-10-09

4.  Role of protein biomarkers in the detection of high-grade disease in cervical cancer screening programs.

Authors:  Charlotte A Brown; Johnannes Bogers; Shaira Sahebali; Christophe E Depuydt; Frans De Prins; Douglas P Malinowski
Journal:  J Oncol       Date:  2012-02-28       Impact factor: 4.375

5.  Clinical Implication of p16, Ki-67, and Proliferating Cell Nuclear Antigen Expression in Cervical Neoplasia: Improvement of Diagnostic Accuracy for High-grade Squamous Intraepithelial Lesion and Prediction of Resection Margin Involvement on Conization Specimen.

Authors:  Tae Hun Kim; Jee Hye Han; Eun Shin; Jae Hong Noh; Hee Seung Kim; Yong Sang Song
Journal:  J Cancer Prev       Date:  2015-03

6.  Immunocytochemical study of TOP2A and Ki-67 in cervical smears from women under routine gynecological care.

Authors:  Adrya Lúcia Peres; Keilla Maria Paz E Silva; Rosângela Ferreira Frade de Araújo; José Luiz de Lima Filho; Mário Ribeiro de Melo Júnior; Danyelly Bruneska Gondim Martins; Nicodemos Teles de Pontes Filho
Journal:  J Biomed Sci       Date:  2016-05-12       Impact factor: 8.410

7.  A comparative analysis of clinical and molecular factors with the stage of cervical cancer in a Brazilian cohort.

Authors:  Sergio M Amaro-Filho; Jonathan E Golub; Gerard J Nuovo; Cynthia B Cunha; José E Levi; Luisa L Villa; Cecília V Andrade; Fabio B Russomano; Aparecida Tristão; Andrea Pires; Alcina F Nicol
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.